Science
BPDCN
Naveen Pemmaraju and Hannah Goulart

Naveen Pemmaraju shares new report on oral DAC+VEN for BPDCN published in Leukemia and Lymphoma Journal

Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared an article co-authored by Hannah Goulart et al. on LinkedIn:

“Delighted to share our brand new original report  just published in Leukemia and Lymphoma, led by Dr Hannah Goulart and Dr Naveen Pemmaraju, MD oral DAC+VEN for patients with BPDCN”

Title: A case series of oral decitabine–cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm

Journal: Leukemia and Lymphoma

Authors: Hannah Goulart, Guillermo Garcia-Manero, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Farhad Ravandi, Muzaffar Qazilbash, Caitlin Rausch, Gabriela Llaurador Caraballo, Sherry Pierce, Naveen Pemmaraju

Read the full article.

Naveen Pemmaraju

Learn more about blastic plasmacytoid dendritic cell neoplasm on OncoDaily.

Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN Caitlin Rausch cancer Courtney D. DiNardo Farhad Ravandi Gabriela Llaurador Caraballo Guillermo Garcia-Manero Hannah Goulart MD Anderson Cancer Center Muzaffar Qazilbash Naval Daver Naveen Pemmaraju OncoDaily Oncology Sherry Pierce Tapan M. Kadia